Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

The Angels Initiative

Stroke prevention

  Chronic Heart Failure

  Free Subscription

Articles published in Lancet

Retrieve available abstracts of 21 articles:
HTML format

Single Articles

    April 2022
  1. BECK-DA-SILVA L, Rohde LE
    Reduction of dietary sodium for heart failure: a step forward.
    Lancet. 2022;399:1361-1363.

  2. EZEKOWITZ JA, Colin-Ramirez E, Ross H, Escobedo J, et al
    Reduction of dietary sodium to less than 100 mmol in heart failure (SODIUM-HF): an international, open-label, randomised, controlled trial.
    Lancet. 2022;399:1391-1400.
    PubMed     Abstract available

    January 2022
  3. SHAH SJ, Borlaug BA, Chung ES, Cutlip DE, et al
    Atrial shunt device for heart failure with preserved and mildly reduced ejection fraction (REDUCE LAP-HF II): a randomised, multicentre, blinded, sham-controlled trial.
    Lancet. 2022 Jan 31. pii: S0140-6736(22)00016.
    PubMed     Abstract available

    August 2021
  4. KARWATH A, Bunting KV, Gill SK, Tica O, et al
    Redefining beta-blocker response in heart failure patients with sinus rhythm and atrial fibrillation: a machine learning cluster analysis.
    Lancet. 2021 Aug 27. pii: S0140-6736(21)01638.
    PubMed     Abstract available

  5. LINDENFELD J, Zile MR, Desai AS, Bhatt K, et al
    Haemodynamic-guided management of heart failure (GUIDE-HF): a randomised controlled trial.
    Lancet. 2021 Aug 26. pii: S0140-6736(21)01754.
    PubMed     Abstract available

  6. CLELAND JGF, Pellicori P
    To master heart failure, first master congestion.
    Lancet. 2021 Aug 26. pii: S0140-6736(21)01914.

  7. Age-stratified and blood-pressure-stratified effects of blood-pressure-lowering pharmacotherapy for the prevention of cardiovascular disease and death: an individual participant-level data meta-analysis.
    Lancet. 2021 Aug 26. pii: S0140-6736(21)01921.
    PubMed     Abstract available

    July 2021
  8. BROWN E, Heerspink HJL, Cuthbertson DJ, Wilding JPH, et al
    SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications.
    Lancet. 2021;398:262-276.
    PubMed     Abstract available

    May 2021

  9. Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis.
    Lancet. 2021;397:1625-1636.
    PubMed     Abstract available

    March 2021
  10. FIGTREE GA, Vernon ST, Hadziosmanovic N, Sundstrom J, et al
    Mortality in STEMI patients without standard modifiable risk factors: a sex-disaggregated analysis of SWEDEHEART registry data.
    Lancet. 2021;397:1085-1094.
    PubMed     Abstract available

    February 2021
  11. LANGLEY RE, Gilbert DC, Duong T, Clarke NW, et al
    Transdermal oestradiol for androgen suppression in prostate cancer: long-term cardiovascular outcomes from the randomised Prostate Adenocarcinoma Transcutaneous Hormone (PATCH) trial programme.
    Lancet. 2021;397:581-591.
    PubMed     Abstract available

    January 2021
  12. VADUGANATHAN M, Fonarow GC, McMurray JJV, Solomon SD, et al
    Considering dose in pharmacological therapies for heart failure - Authors' reply.
    Lancet. 2021;397:275.

  13. SEEDAT Z, Itty K
    Considering dose in pharmacological therapies for heart failure.
    Lancet. 2021;397:274-275.

    November 2020
  14. PONIKOWSKI P, Kirwan BA, Anker SD, McDonagh T, et al
    Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial.
    Lancet. 2020 Nov 12. pii: S0140-6736(20)32339.
    PubMed     Abstract available

    August 2020
  15. ZANNAD F, Ferreira JP, Pocock SJ, Anker SD, et al
    SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials.
    Lancet. 2020 Aug 28. pii: S0140-6736(20)31824.
    PubMed     Abstract available

  16. BRAININ M, Sliwa K
    WSO and WHF joint position statement on population-wide prevention strategies.
    Lancet. 2020;396:533-534.

    In sepsis-induced heart failure, extracorporeal membrane oxygenation can provide support.
    Lancet. 2020;396:515-517.

    May 2020
  18. PSOTKA MA, Teerlink JR
    Assessing the lifetime benefit of heart failure therapies.
    Lancet. 2020 May 21. pii: S0140-6736(20)30929.

  19. VADUGANATHAN M, Claggett BL, Jhund PS, Cunningham JW, et al
    Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials.
    Lancet. 2020 May 21. pii: S0140-6736(20)30748.
    PubMed     Abstract available

    October 2019
  20. SUCHARD MA, Schuemie MJ, Krumholz HM, You SC, et al
    Comprehensive comparative effectiveness and safety of first-line antihypertensive drug classes: a systematic, multinational, large-scale analysis.
    Lancet. 2019 Oct 24. pii: S0140-6736(19)32317.
    PubMed     Abstract available

    September 2019
  21. HAUSENLOY DJ, Kharbanda RK, Moller UK, Ramlall M, et al
    Effect of remote ischaemic conditioning on clinical outcomes in patients with acute myocardial infarction (CONDI-2/ERIC-PPCI): a single-blind randomised controlled trial.
    Lancet. 2019 Sep 6. pii: S0140-6736(19)32039.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Chronic Heart Failure is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.